Impact of GH administration on skeletal endpoints in adults with overweight/obesity.
Laura E DichtelMelanie Schorr HainesAnu V GerweckBryan BollingerAllison KimballDavid SchoenfeldMiriam A BredellaKaren K MillerPublished in: European journal of endocrinology (2022)
GH administration for 18 months increased bone turnover in adults with overweight/obesity. It also decreased some measures of BMD, bone microarchitecture, and bone strength, which all returned to pre-treatment levels 6 months post-therapy. Whether GH administration increases BMD with longer treatment duration, or after mineralization of an expanded remodeling space post-treatment, requires further investigation.